One of the most perplexing institutions in this country is Big Pharma. Unlike any other industry, success is not the end goal. Rather, “controlled failure” represents this sector’s ultimate objective.

The point is rather obvious. If pharmaceutical companies developed medical breakthroughs that completely cured diseases, they would of course receive a one-off sentiment burst. But after insurance-armed patients have finished their procedures, they are no longer patients. And what medical institution can survive if it doesn’t have an abundance of sick customers?

But placing blame on Big Pharma has always carried the undesirable “conspiracy theory” tag. While we instinctively recognize that pharmaceuticals profit from disease management, we’re likely to hear this from an Alex Jones-type broadcast. Pursuing this logic leads to the inevitable credibility suck.

That is until a Bloomberg article set the record straight.

93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.

Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!

Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!

    Big Pharma and Its Not-So-Delicate Balancing Act

    Contributor Joe Nocera detailed the intriguing story behind Gilead Sciences and its groundbreaking Hepatitis C drug Sovaldi. Unlike every other concoction from Big Pharma, biomedical experts designed Sovaldi to fully eradicate the Hepatitis C virus.

    Although the initial costs associated with the treatment are expensive, health insurers willingly absorbed most of them. The reason? Sovaldi is incredibly effective. After a treatment process that lasts a few weeks, patients receive a clean bill of health. According to available data, it’s unlikely that the liver-killing disease will return.

    For Big Pharma, this is an unbelievable achievement. Prior to this, medial institutions have had virtually a 0% success rate for curing serious ailments. But at the same time, Nocera implies that Sovaldi doomed Gilead.

    Is This a New Age for Pharmaceuticals?

    On the other end of the spectrum, AbbVie introduced its own Hepatitis C therapy. However, its variant was only marginally effective compared to Gilead’s solution. After all, Sovaldi meant a permanent respite from the awful condition.

    Still, Wall Street apparently loved AbbVie more. In this sick world we live in, it’s better for Big Pharma to produce ineffective therapies that require constant care. Gilead’s way leads to a one-off payment. AbbVie rakes in consistent cash flow.

    Or does it? While AbbVie shares have witnessed more success, Gilead shares fell due to issues not directly related to opportunity costs. And in the long run, I argue that controlled failure is not a recipe for lasting success.

    Even in a sick world, people can recognize a good deal when they see one.

    Prosperous Regards,
    Kenneth Ameduri
    Chief Editor,

    Governments Have Amassed ungodly Debt Piles and Have Promised Retirees Unreasonable Amounts of Entitlements, Not In Line with Income Tax Collections. The House of Cards Is Set To Be Worse than 2008! Rising Interest Rates Can Topple The Fiat Monetary Structure, Leaving Investors with Less Than Half of Their Equity Intact!

    Protect Yourself Now, By Building A Fully-Hedged Financial Fortress!

      Legal Notice: This work is based on public filings, current events, interviews, corporate press releases, and what we’ve learned as financial journalists. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment, or tax professional should be sought.  Never base any decision off of our emails.  Never base any decision off of our emails. Please use our site as a place to get ideas. Enjoy our videos and news analysis, but never make an investment decision off of anything we say. Please review our entire disclaimer at